Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance

In obesity, macrophages and other immune cells accumulate in insulin target tissues, promoting a chronic inflammatory state and insulin resistance. Galectin-3 (Gal3), a lectin mainly secreted by macrophages, is elevated in both obese subjects and mice. Administration of Gal3 to mice causes insulin r...

Full description

Saved in:
Bibliographic Details
Published inCell Vol. 167; no. 4; pp. 973 - 984.e12
Main Authors Li, Pingping, Liu, Shuainan, Lu, Min, Bandyopadhyay, Gautum, Oh, Dayoung, Imamura, Takeshi, Johnson, Andrew M.F., Sears, Dorothy, Shen, Zhufang, Cui, Bing, Kong, Lijuan, Hou, Shaocong, Liang, Xiao, Iovino, Salvatore, Watkins, Steven M., Ying, Wei, Osborn, Olivia, Wollam, Joshua, Brenner, Martin, Olefsky, Jerrold M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 03.11.2016
Subjects
Online AccessGet full text
ISSN0092-8674
1097-4172
1097-4172
DOI10.1016/j.cell.2016.10.025

Cover

Loading…
More Information
Summary:In obesity, macrophages and other immune cells accumulate in insulin target tissues, promoting a chronic inflammatory state and insulin resistance. Galectin-3 (Gal3), a lectin mainly secreted by macrophages, is elevated in both obese subjects and mice. Administration of Gal3 to mice causes insulin resistance and glucose intolerance, whereas inhibition of Gal3, through either genetic or pharmacologic loss of function, improved insulin sensitivity in obese mice. In vitro treatment with Gal3 directly enhanced macrophage chemotaxis, reduced insulin-stimulated glucose uptake in myocytes and 3T3-L1 adipocytes and impaired insulin-mediated suppression of glucose output in primary mouse hepatocytes. Importantly, we found that Gal3 can bind directly to the insulin receptor (IR) and inhibit downstream IR signaling. These observations elucidate a novel role for Gal3 in hepatocyte, adipocyte, and myocyte insulin resistance, suggesting that Gal3 can link inflammation to decreased insulin sensitivity. Inhibition of Gal3 could be a new approach to treat insulin resistance. [Display omitted] •Galectin-3 blood levels are elevated in human and rodent obesity•Galectin-3 directly impairs insulin action in myocytes, adipocytes, and hepatocytes•Galectin-3 treatment causes systemic insulin resistance in vivo•Galectin-3 loss of function improves insulin sensitivity in obesity A circulating lectin secreted by macrophages in obese individuals drives insulin resistance and glucose intolerance by directly binding the insulin receptor and antagonizing downstream metabolic responses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
co-first author
Lead contact: P. L.
ISSN:0092-8674
1097-4172
1097-4172
DOI:10.1016/j.cell.2016.10.025